Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

JMP Securities Moves Myriad Genetics to Strong Buy


JMP Securities upgraded Myriad Genetics (MYGN) to strong buy from outperform, after the company on Tuesday beat expectations with its quarterly results.

The company on Tuesday posted a 22 cents earnings per share loss in the second quarter. But analyst Charles Duncan says the second quarter results beat his and consensus estimates. He expects the biotechnology company to have continued growth in its Predictive Medicine revenue estimates for fiscal year 2006 (ending June) and beyond, as a result of three marketing initiatives including the Direct-to-Consumer campaign. He says that heightened visibility from the compan's new drug pipeline is expected to come in the near term including, additional data about studies on its studies of treatments for Alzheimer's disease. He raises his $25 stock price target to $29.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus